Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
Authors:
Top Cited Papers
- 7 May 2025
- journal article
- Published by Elsevier in The Lancet
- Vol. 405 (10491) , 1757-1768
Abstract
No abstract availableKeywords
Funding Information
- NewAmsterdam Pharma
This publication has 28 references indexed in Scilit:
- Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trialJournal of Clinical Lipidology, 2023
- LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysisAtherosclerosis, 2023
- Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without AtherosclerosisJAMA Cardiology, 2021
- Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United StatesAmerican Journal of Preventive Cardiology, 2020
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive SummaryJACC, 2019
- Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid AssociationJournal of Clinical Lipidology, 2017
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic InterventionsJAMA, 2016
- Effect of Very High-Intensity Statin Therapy on Regression of Coronary AtherosclerosisJAMA, 2006
- Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular DiseaseJACC, 2006
- Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial diseaseThe American Journal of Cardiology, 2003